# A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.

> **NCT07366866** · PHASE1 · RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Autoimmune Disease

## Interventions

- **DRUG:** GenSci136
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07366866
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2027-02-07
- **Final completion:** 2027-03-09
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07366866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07366866, "A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07366866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*